Henri Termeer discusses his path to Genzyme, the approval of Ceredase and the drawn-out negotiations with eventual acquirer Sanofi.<img src="http://feeds.feedburner.com/~r/nbt/podcast/current/~4/kjL_Or-ZoIA" height="1" width="1" alt=""/> For information regarding your data privacy, visit <a href="https://www.acast.com/privacy">acast.com/privacy</a>

Henri Termeer discusses his path to Genzyme, the approval of Ceredase and the drawn-out negotiations with eventual acquirer Sanofi. For information regarding your data privacy, visit acast.com/privacy

Henri Termeer discusses his path to Genzyme, the approval of Ceredase and the drawn-out negotiations with eventual acquirer Sanofi. For information regarding your data privacy, visit <a href="https://www.acast.com/privacy" rel="noopener noreferrer">acast.com/privacy</a>

First Rounder: Henri Termeer

Nature Biotechnology's First Rounders podcast is a series of conversations with founders, financers and developers from biotech's past, present and future. <hr> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.

Nature Biotechnology's First Rounders podcast is a series of conversations with founders, financers and developers from biotech's past, present and future. Hosted on Acast. See acast.com/privacy for more information.

Nature Biotechnology's First Rounders podcast is a series of conversations with founders, financers and developers from biotech's past, present and future. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer">acast.com/privacy</a> for more information.

Share First Rounder: Henri Termeer

Sign up to save your podcasts

First Rounder: Henri Termeer

First Rounder: Henri Termeer